On page 2133 in the 17 February 2011, issue, there is an error in Table 3. The penultimate column should be headed “relapse-free” not “remission-free.” The corrected table is shown.
© 2011 by The American Society of Hematology
2011
Ensor HM, Schwab C, Russell LJ, et al. Demographic, clinical, and outcome features of children with acute lymphoblastic leukemia and CRLF2 deregulation: results from the MRC ALL97 clinical trial. Blood. 2011;117(7):2129–2136.. Blood 2011; 117 (18): 5009. doi: https://doi.org/10.1182/blood-2011-03-344689
Download citation file:
On page 2133 in the 17 February 2011, issue, there is an error in Table 3. The penultimate column should be headed “relapse-free” not “remission-free.” The corrected table is shown.
Advertisement intended for health care professionals
Group . | n . | No remission, n (%) . | Deaths in first remission, n (%) . | Relapses, n (%) . | Total deaths, n (%) . | Survival, % (95% CI) at 5 y . | ||
---|---|---|---|---|---|---|---|---|
Event-free . | Relapse-free . | Overall . | ||||||
Total cohort | 865 | 9 (1) | 31 (4) | 182 (21) | 132 (15) | 77 (74-80) | 81 (78-83) | 87 (84-89) |
CRLF2-d | 52 | 2 (4) | 6 (12) | 16 (31) | 22 (42) | 58 (43-70) | 68 (52-80) | 69 (55-80) |
Others | 813 | 7 (1) | 25 (3) | 166 (20) | 110 (14) | 79 (76-81) | 82 (79-84) | 88 (85-90) |
DS cohort | 26 | 3 (12) | 7 (27) | 4 (15) | 14 (54) | 46 (27-64) | 76 (47-90) | 54 (33-71) |
CRLF2-d | 14 | 2 (14) | 5 (36) | 3 (21) | 10 (71) | 29 (9-52) | 58 (18-84) | 36 (13-59) |
Others | 12 | 1 (8) | 2 (17) | 1 (8) | 4 (33) | 67 (34-86) | 89 (43-98) | 75 (41-91) |
Non-DS cohort | 839 | 6 (1) | 24 (3) | 178 (21) | 118 (14) | 78 (75-81) | 81 (78-83) | 88 (85-90) |
CRLF2-d | 38 | 0 (0) | 1 (3) | 13 (34) | 12 (32) | 68 (51-81) | 70 (52-82) | 81 (65-91) |
Others | 801 | 6 (1) | 23 (3) | 165 (21) | 106 (13) | 79 (76-81) | 81 (79-84) | 88 (86-90) |
Group . | n . | No remission, n (%) . | Deaths in first remission, n (%) . | Relapses, n (%) . | Total deaths, n (%) . | Survival, % (95% CI) at 5 y . | ||
---|---|---|---|---|---|---|---|---|
Event-free . | Relapse-free . | Overall . | ||||||
Total cohort | 865 | 9 (1) | 31 (4) | 182 (21) | 132 (15) | 77 (74-80) | 81 (78-83) | 87 (84-89) |
CRLF2-d | 52 | 2 (4) | 6 (12) | 16 (31) | 22 (42) | 58 (43-70) | 68 (52-80) | 69 (55-80) |
Others | 813 | 7 (1) | 25 (3) | 166 (20) | 110 (14) | 79 (76-81) | 82 (79-84) | 88 (85-90) |
DS cohort | 26 | 3 (12) | 7 (27) | 4 (15) | 14 (54) | 46 (27-64) | 76 (47-90) | 54 (33-71) |
CRLF2-d | 14 | 2 (14) | 5 (36) | 3 (21) | 10 (71) | 29 (9-52) | 58 (18-84) | 36 (13-59) |
Others | 12 | 1 (8) | 2 (17) | 1 (8) | 4 (33) | 67 (34-86) | 89 (43-98) | 75 (41-91) |
Non-DS cohort | 839 | 6 (1) | 24 (3) | 178 (21) | 118 (14) | 78 (75-81) | 81 (78-83) | 88 (85-90) |
CRLF2-d | 38 | 0 (0) | 1 (3) | 13 (34) | 12 (32) | 68 (51-81) | 70 (52-82) | 81 (65-91) |
Others | 801 | 6 (1) | 23 (3) | 165 (21) | 106 (13) | 79 (76-81) | 81 (79-84) | 88 (86-90) |
ALL indicates acute lymphoblastic leukemia; CI, confidence interval; and DS, Down syndrome.
Advertisement intended for health care professionals
Advertisement intended for health care professionals
Advertisement intended for health care professionals